Oral Tirzepatide — The Future of Weight Loss Pills copertina

Oral Tirzepatide — The Future of Weight Loss Pills

Oral Tirzepatide — The Future of Weight Loss Pills

Di: Inception Point Ai
Ascolta gratuitamente

A proposito di questo titolo

 Eli Lilly's orforglipron achieved 27 pounds of weight loss in trials, potentially revolutionizing obesity treatment with a daily pill that needs no refrigeration. Dr. Ben Synth examines the science behind oral GLP-1 drugs, their potential to democratize access worldwide, and the dangers of unregulated compounded alternatives that harmed hundreds of patients.

For more content like this, visit QuietPlease.aiCopyright 2025 Inception Point Ai Disturbo fisico e malattia Igiene e vita sana
Episodi
  • Oral Tirzepatide — Discover the future of weight loss with Dr. Ben Synth

    Oral Tirzepatide — Discover the future of weight loss with Dr. Ben Synth
    Apr 7 2026
    Join Dr. Ben Synth as he investigates the high-stakes race to transform injectable weight loss drugs like tirzepatide into a pill—exploring the groundbreaking science of shrinking massive molecules, the potential to democratize obesity treatment for billions, and the dangerous shortcuts emerging as desperation outpaces safety.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI
    Mostra di più Mostra meno
    1 min
  • Oral Tirzepatide — The Future of Weight Loss Pills - The Compounding Catastrophe

    Oral Tirzepatide — The Future of Weight Loss Pills - The Compounding Catastrophe
    Apr 7 2026
    Ben Synth examines how tirzepatide shortages drove desperate patients to unregulated compounding pharmacies offering untested oral versions, resulting in over 300 adverse events. The episode explores the collision between pharmaceutical innovation, regulatory gaps, and a healthcare system struggling to meet demand for breakthrough weight-loss treatments.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI
    Mostra di più Mostra meno
    29 min
  • Oral Tirzepatide — The Future of Weight Loss Pills - A Pill for the World

    Oral Tirzepatide — The Future of Weight Loss Pills - A Pill for the World
    Apr 7 2026
    Ben Synth explores orforglipron, Eli Lilly's daily oral weight loss pill showing 27-pound average loss in Phase 3 trials. Unlike injectable alternatives requiring refrigeration and needles, this room-temperature tablet could revolutionize global obesity treatment by reaching underserved populations. We examine clinical data, access barriers, and why slightly reduced efficacy at massive scale beats maximum results for privileged few.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI
    Mostra di più Mostra meno
    24 min
Ancora nessuna recensione